Infectious Disease Clinics of North America volume 21, issue 4, P1055-1090 2007 DOI: 10.1016/j.idc.2007.08.008 View full text
|
|
Share
Anastasia Antoniadou, Helen Giamarellou

Abstract: Febrile neutropenia is a syndrome commonly anticipated in patients receiving treatment for cancer. Its management for the last three decades has included the prompt administration of empiric antibacterial therapy, which resulted in a reduction in mortality. Challenges remain the administration of the most appropriate empiric treatment regimen adapted to evolving and changing epidemiology of infections in neutropenic patients and resistance rates; the development of markers of early diagnosis of severe bacteria…

expand abstract